JP2013023499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013023499A5 JP2013023499A5 JP2012154328A JP2012154328A JP2013023499A5 JP 2013023499 A5 JP2013023499 A5 JP 2013023499A5 JP 2012154328 A JP2012154328 A JP 2012154328A JP 2012154328 A JP2012154328 A JP 2012154328A JP 2013023499 A5 JP2013023499 A5 JP 2013023499A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- antagonist antibody
- pcsk9 antagonist
- pcsk9
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims 23
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 7
- 108010028554 LDL Cholesterol Proteins 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 4
- 229960005370 atorvastatin Drugs 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 229960000672 rosuvastatin Drugs 0.000 claims 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 4
- 229960002855 simvastatin Drugs 0.000 claims 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 4
- 101710172072 Kexin Proteins 0.000 claims 3
- 108090000787 Subtilisin Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229960005110 cerivastatin Drugs 0.000 claims 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960003765 fluvastatin Drugs 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 229960004844 lovastatin Drugs 0.000 claims 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 2
- 229950009116 mevastatin Drugs 0.000 claims 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 2
- 229960002797 pitavastatin Drugs 0.000 claims 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 2
- 229960002965 pravastatin Drugs 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 230000000923 atherogenic effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507865P | 2011-07-14 | 2011-07-14 | |
| US61/507,865 | 2011-07-14 | ||
| US201261614312P | 2012-03-22 | 2012-03-22 | |
| US61/614,312 | 2012-03-22 | ||
| US201261643063P | 2012-05-04 | 2012-05-04 | |
| US61/643,063 | 2012-05-04 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017099458A Division JP2017145256A (ja) | 2011-07-14 | 2017-05-19 | 抗ｐｃｓｋ９抗体を用いた処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013023499A JP2013023499A (ja) | 2013-02-04 |
| JP2013023499A5 true JP2013023499A5 (enExample) | 2015-08-27 |
Family
ID=46758800
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012154328A Pending JP2013023499A (ja) | 2011-07-14 | 2012-07-10 | 抗ｐｃｓｋ９抗体を用いた処置 |
| JP2017099458A Pending JP2017145256A (ja) | 2011-07-14 | 2017-05-19 | 抗ｐｃｓｋ９抗体を用いた処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017099458A Pending JP2017145256A (ja) | 2011-07-14 | 2017-05-19 | 抗ｐｃｓｋ９抗体を用いた処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140161821A1 (enExample) |
| EP (1) | EP2731623A1 (enExample) |
| JP (2) | JP2013023499A (enExample) |
| KR (1) | KR20140021708A (enExample) |
| CN (1) | CN104093423A (enExample) |
| AU (1) | AU2012282130B2 (enExample) |
| BR (1) | BR112014000392A2 (enExample) |
| CA (1) | CA2840482C (enExample) |
| HK (1) | HK1202804A1 (enExample) |
| MX (1) | MX2014000578A (enExample) |
| RU (1) | RU2576034C2 (enExample) |
| WO (1) | WO2013008185A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN110711248A (zh) | 2011-01-28 | 2020-01-21 | 赛诺菲生物技术公司 | 包含针对pcsk9的人抗体的药物组合物 |
| MX2014000578A (es) * | 2011-07-14 | 2014-04-30 | Pfizer | Tratamiento con anticuerpos anti-pcsk9. |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2992345T3 (es) | 2011-09-16 | 2024-12-11 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10058630B2 (en) | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US20150306281A1 (en) * | 2014-04-28 | 2015-10-29 | Nalini Marie Rajamannan | Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| AU2014274844B2 (en) | 2013-06-07 | 2019-11-28 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| EP3068803B1 (en) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN107072955B (zh) | 2014-05-15 | 2021-06-18 | 拉尼医疗有限公司 | 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法 |
| US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| RU2735521C2 (ru) | 2014-07-16 | 2020-11-03 | Санофи Байотекнолоджи | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) |
| WO2016020799A1 (en) * | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
| US20170224816A1 (en) * | 2014-08-06 | 2017-08-10 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
| US10472424B2 (en) | 2014-09-23 | 2019-11-12 | Pfizer Inc. | Treatment with anti-PCSK9 antibodies |
| JP2018516624A (ja) * | 2015-04-15 | 2018-06-28 | コンシーヴァルブ エルエルシー | 自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法 |
| US10772956B2 (en) | 2015-08-18 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
| CN108401419A (zh) * | 2015-09-08 | 2018-08-14 | 因库博实验室有限责任公司 | 使用可吞服药物递送装置递送到肠道内腔中的pcsk9抗体制剂 |
| RU2731202C2 (ru) | 2015-10-08 | 2020-08-31 | Макродженикс, Инк. | Комбинированная терапия для лечения рака |
| US10793643B2 (en) | 2015-12-31 | 2020-10-06 | Jiangsu Hengrui Medicine Co., Ltd. | PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof |
| US20200270365A1 (en) | 2016-01-05 | 2020-08-27 | Jiangsu Hengrui Medicine Co., Ltd. | Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof |
| PL3426680T3 (pl) * | 2016-03-10 | 2025-03-31 | Acceleron Pharma Inc. | Białka wiążące receptor aktywiny typu 2 i ich zastosowania |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| EP3609532A1 (en) | 2017-04-13 | 2020-02-19 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
| EP4470609A3 (en) | 2019-01-18 | 2025-03-12 | Astrazeneca AB | Pcsk9 inhibitors and methods of use thereof |
| US20250368753A1 (en) | 2021-10-21 | 2025-12-04 | Flagship Pioneering Innovations Vi, Llc | Modulators of proprotein convertase subtilisin/kexin type 9 (pcsk9) |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US4936746A (en) | 1988-10-18 | 1990-06-26 | United Technologies Corporation | Counter-rotation pitch change system |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| FR2695140B1 (fr) | 1992-08-06 | 1994-11-04 | Aetsrn | Procédé d'inactivation virale des produits plasmatiques par des fluides supercritiques ou subcritiques. |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| DE4308101C1 (de) | 1993-03-15 | 1994-07-28 | Degussa | Verfahren zur Herstellung platingruppenmetallhaltiger Hydrierkatalysatoren auf Aktivkohle |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| CN102580084B (zh) * | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
| JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Ｐｃｓｋ９拮抗劑類 |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| AU2011225716A1 (en) * | 2010-03-11 | 2012-09-27 | Pfizer Inc. | Antibodies with pH dependent antigen binding |
| CN110711248A (zh) * | 2011-01-28 | 2020-01-21 | 赛诺菲生物技术公司 | 包含针对pcsk9的人抗体的药物组合物 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| MX2014000578A (es) * | 2011-07-14 | 2014-04-30 | Pfizer | Tratamiento con anticuerpos anti-pcsk9. |
-
2012
- 2012-07-10 MX MX2014000578A patent/MX2014000578A/es unknown
- 2012-07-10 KR KR1020147000640A patent/KR20140021708A/ko not_active Ceased
- 2012-07-10 US US14/232,559 patent/US20140161821A1/en not_active Abandoned
- 2012-07-10 RU RU2013156848/15A patent/RU2576034C2/ru not_active IP Right Cessation
- 2012-07-10 CA CA2840482A patent/CA2840482C/en not_active Expired - Fee Related
- 2012-07-10 WO PCT/IB2012/053534 patent/WO2013008185A1/en not_active Ceased
- 2012-07-10 EP EP12753240.6A patent/EP2731623A1/en not_active Withdrawn
- 2012-07-10 AU AU2012282130A patent/AU2012282130B2/en not_active Ceased
- 2012-07-10 CN CN201280044688.2A patent/CN104093423A/zh active Pending
- 2012-07-10 HK HK15103421.6A patent/HK1202804A1/xx unknown
- 2012-07-10 BR BR112014000392A patent/BR112014000392A2/pt not_active Application Discontinuation
- 2012-07-10 JP JP2012154328A patent/JP2013023499A/ja active Pending
-
2016
- 2016-02-05 US US15/016,873 patent/US20160152734A1/en not_active Abandoned
-
2017
- 2017-05-19 JP JP2017099458A patent/JP2017145256A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013023499A5 (enExample) | ||
| RU2013156848A (ru) | Лечение антителами против pcsk9 | |
| JP2019514907A5 (enExample) | ||
| JP2022177142A5 (enExample) | ||
| RU2013139727A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| JP2017522316A5 (enExample) | ||
| AU2013296493B2 (en) | Methods for treatment of atherosclerosis | |
| JP2017528427A5 (enExample) | ||
| JP2015187125A5 (enExample) | ||
| JP2016538277A5 (enExample) | ||
| JP2022000443A5 (enExample) | ||
| JP2018508551A5 (ja) | 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物 | |
| JP2017506626A5 (enExample) | ||
| RU2017101705A (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| RU2009139221A (ru) | Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в | |
| FI3448426T3 (fi) | Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon | |
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2016538248A5 (enExample) | ||
| RU2015101113A (ru) | Антитела против pcsk9, составы, дозы и способы применения | |
| WO2014153424A1 (en) | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) | |
| IL292829A (en) | Fixed dose combinations containing etc1002 and one or more statins to treat or reduce cardiovascular risk | |
| FI3416684T3 (fi) | Menetelmiä ateroskleroosin hoitamiseksi tai ehkäisemiseksi antamalla ANGPTL3:n inhibiittoria | |
| Lee et al. | Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia | |
| WO1998001100A2 (en) | Method for treating homozygous familial hypercholesterolemia |